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COMPLIANCE INFLUENCE, PERSISTENCE AND THE BLOOD PRESSURE 
CONTROL GRADE ASSOCIATED WITH THE INCIDENCE OF 
CARDIOVASCULAR EVENTS AND THE SANITARY COSTS IN 
CONSUMPTION OF FIXED-DOSES IN THE ARTERIAL HYPERTENSION 
TREATMENT
Sicras-Mainar A1, Galera J2, Muñoz-Ortí G3, Navarro-Artieda R4
1Directorate of Planning, Badalona Serveis Assistencials, Badalona, Barcelona, Spain; 2Novartis 
Farmaceutica S.A., Barcelona, Spain; 3Hospital Universitari Germans Trias i Pujol, Barcelona, 
Spain
OBJECTIVES: To determine the incidence of cardiovascular events (CVE) and the 
sanitary costs in function of the compliance, persistence and blood pressure control; 
comparing patients consuming ﬁ xed-doses (FD) in front of free-doses (FD) in the 
treatment of HTA. METHODS: Observational-multicentric design. It was included 
patients >30 years appertaining to six team of primary care and two hospitals, that 
started pharmacological treatment for hypertension during 2006. It was established 
two study groups: FD (IECA/diuretics; ARA II/diuretics) and FD (IECA + DIU; ARA 
II + DIU, separately). Main measures: socio-demographics, co-morbidity, parameters, 
Charlson-index, compliance, persistence and control therapeutical objects (criteria: 
ESH-ESC). It was determined the accumulated incidence tax of CVE and a total-cost 
model (differentiating: sanitary/direct; non-sanitary/indirect). The patients’ pursuit 
was realized during two years. Statistic analysis: logistic regression, proportional risk 
model of Cox and the ANCOVA, P < 0.05. RESULTS: It was recruited 1605 patients, 
1.112 (69.3%) in FD and 493 (30.7%) in FD, P < 0.001; age average: 69.4 (12.2) 
years; women: 55.5%. Patients in FD were associated with the isquemic cardiopathy 
OR = 1.4 (CI of 95%: 1.1–2.0) and organic insufﬁ ciencies OR = 1.5 (IC of 95%: 
1.2–2.1), P < 0.031. Patients in FD showed a better therapeutic compliance (77.6 vs. 
71.9; P < 0.001) and treatment persistence at 24 months (62.1% [CI of 95%: 56.3–
67.9%] vs. 49.7% [CI of 95%: 38.5–60.9%]; P < 0.001. The optimum control of the 
arterial pressure in FD was higher (48.9% [CI of 95%: 43.0–54.8%] vs. 46.7% [CI 
of 95%: 35.6–57.8%]; P < 0.001). The accumulated incidence tax of vasculocerebral 
accident in FD was 4.6% vs. 2.4%; p = 0.041. The total cost in FD was lower (c1650.7 
vs. c1674.8; P < 0.001), in specialized care (c316.1 vs. c382.9; P < 0.001) and loses 
of labour productivity (c44.5 vs. c88.4; P < 0.001). CONCLUSIONS: Treatment of 
compliance and persistence for hypertension in FD improve the therapeutical control, 
causing a reduction of CVE and total sanitary costs.
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COST OF ANALYSIS OF THE ADVERSE EFFECTS OF THE 
ANTIARRYTHMIC DRUGS IN THE CLINCAL PRACTICE IN SPAIN
Pastor Fuentes A1, Moreno Reviriego S2, Garcia Coscolin T3, Pérez Alcántara F4
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OBJECTIVES: Antiarrhythmic drugs (AADs) are considered the ﬁ rst-line treatment of 
atrial ﬁ brillation (AF). However, they present a high adverse effects (AEs) rate. The 
aim of the present study is to know the health resources and the costs associated with 
the management of AEs of main AADs. METHODS: The incidence of AE’s of main 
AADs (amiodarone, sotalol, ﬂ ecainide and propafenone) has been obtained from the 
Summary of product characteristics or correspondent clinical trials. The use of health 
resources associated with the management of the AEs has been evaluated by a panel 
of cardiology experts. Finally, all these clinical data regarding AE’s incidence derived, 
has been combined with economic data from the Spanish literature and e- salud 
data,an Spanish database about health care costs. The study has been carried using 
National Health System perspective. RESULTS: The most expensive AEs have been 
pulmonary ﬁ brosis: c2,177.49, cardiac events (mainly tachycardia or bradycardia): 
c1,422.08, and endocrine disorders (as hyperthyroidism: c244.06c and hypothy-
roidsm: c239.06 c). When costs are analyzed in relation with the drug to which are 
associated, results are as follow: sotalol has been associated with the highest costs: 
c269.42, followed by ﬂ ecainide: 132.25 c, and amiodarone: 127,82, whereas propafe-
none has been associated to the lowest cost: c48.09. However, although amiodarone 
is not the AAD associated with the highest cost, considering current Spanish AADs 
market, it is the one that has more economic repercussion. CONCLUSIONS: Current 
AADs may cause AEs and their management is related to health resources consump-
tion. Pulmonary and cardiac events have been associated to the major cost. Consider-
ing current clinical practice in Spain, amiodarone is the treatment that supposes a 
major budget impact for the National Health Service.
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ECONOMICS ESTIMATION OF SIDE EFFECTS CORRECTION 
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RUSSIAN HEALTH
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OBJECTIVES: To assess the cost of the basic course of pharmacotherapy of arterial 
hypertension (AH) of inhibitors-ACE, direct costs associated with the correction of 
side effects (SE), developing on the background of their application with further 
pharmacoeconomics evaluation of inhibitors-ACE. METHODS: Cost analysis, model-
ing. a consideration of the basic price of therapy trade names (TN) inhibitors-ACE 
INN: enalapril, lisinopril and the calculation of direct costs associated with correction 
of SE in patients diagnosed with stage II AH. Medical patients’ route, the cost structure 
were modeled by questioning physicians, cardiologists of Institute of Gerontology, 
Clinical Hospital ¹ 55, Moscow. The study takes into account the cost: symptomatic 
therapy, specialist consultations, emergency care, hospital bed-days, laboratory and 
instrumental manipulations. Data registered in RF TN obtained from the site www.
regmed.ru, information about prices—www.medlux.ru, www.cardioweb.ru. We took 
into account recommendations of standards of care for patients with AH, developed 
by Health Ministry of Russia. The cost of the basic course of pharmacotherapy and 
PE are estimated at 30-day time period for 1 patient. Average daily dose the drugs 
accounted for enalapril—5 mg/day, lisinopril—10 mg/day. RESULTS: The develop-
ment of side effects (cough, arterial hypotension, allergies, headache, etc.) was the 
cause of drug withdrawal enalapril in 5.3% of patients, lisinopril at 3.8% of patients. 
The study calculated the cost of courses were the main pharmacotherapy TN lisinopril 
and enalapril, ranging from 30 to 245 Rubles, corrective therapy—from 284 to 583 
Rubles. In the economic evaluation of SE was the least expensive scheme with drug 
enalapril, which is more advantageous from an economic position. CONCLUSIONS: 
The economic analysis of side effects developing on the background of the basic course 
of pharmacotherapy, is relevant assessment to improve the quality and credibility of 
pharmacoeconomics studies of drugs.
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UPTAKE AND COSTS OF IMAGING MODALITIES IN PACEMAKER-
IMPLANTED AND NON-IMPLANTED PATIENTS
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OBJECTIVES: Magnetic resonance imaging (MRI) is considered the gold standard for 
imaging of the brain, spinal cord, musculoskeletal system, and complex cardiac 
malfor mations. However, pacemaker implant is a contraindication to MRI, and thus 
a barrier to access in pacemaker-implanted patients for this essential diagnostic tech-
nology. An analysis of Medicare fee-for-service data was conducted to estimate the 
difference in MRI uptake rates of pacemaker-implanted and non-implanted Medicare 
benﬁ ciaries. METHODS: The data comprised the fee-for-service portion of the 2008 
Medicare patient population. Two issues were examined: the prevalence of the diseases 
for which MRI is the preferred imaging modality, and the uptake rates of all imaging 
modalities for MRI-indicated beneﬁ ciaries with pacemaker implants compared with 
those having no implants. For each of diseases for which MRI is the preferred modality 
we also identiﬁ ed any trade-offs between lower MRI rates and higher rates for other 
imaging modalities in pacemaker-implanted and non-implanted patients, and potential 
cost implications substituting MRI with other imaging modalities. RESULTS: The 
Medicare data indicated MRI uptake was nil in the pacemaker-implanted population 
where 13% of patients without any implant received MRI in 2008 suggesting that 
clinical practice is in line with the contraindication for MRI in pacemaker patients. 
Consequently, uptake of other imaging approaches including CT, ultrasound, nuclear, 
x-ray was greater in the MRI-indicated cohort of pacemaker patients (54%, 65%, 
25%, 82%, respectively) compared to the similar non-implanted cohort (38%, 48%, 
18%, 73%, respectively). It was estimated that access to MRI (i.e. patients implanted 
with MRI-compatible pacemakers) would generate up to 21% reduced diagnostic 
costs compared with no access to MRI (i.e. patients implanted with older generation 
pacemakers). CONCLUSIONS: Increased access to the diagnostic superiority of MRI 
may provide a more efﬁ cient allocation of diagnostic resources for pacemaker patients; 
this increased access can be provided with the availability in the market of new pace-
makers engineered for MRI compatibility.
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OBJECTIVES: As part of a broader HTA project on ablation procedures for atrial 
ﬁ brillation (A-AF), objective of this study was to quantify consumption of resources 
and calculate cost of A-AF in comparison with current reimbursement in Italy. 
METHODS: A questionnaire was sent to the Italian electrophysiology (EP) centres 
identiﬁ ed by AIAC (Italian Society of Cardiac Pacing and Arrhythmology) to collect, 
2008 data on: number of procedures; use of pre-post ablation diagnostics, consum-
ables, electro-anatomic mapping, anaesthesia/analgesia, EP laboratory occupancy 
time, staff employed; EP laboratory equipment; duration of hospitalization. Bottom-
up costing of resources was performed based on average costs from a sub-sample of 
4 hospitals, national tariffs or published data. Average procedure cost was calculated 
based on mathematical (m-mat) and geometrical (m-geo) means. Final endpoint was 
the comparison between DRG-518 regional reimbursement values and full hospital 
costs for ablation treatment. RESULTS: A total of 52/87 (60%) AIAC centres replied 
to the questionnaire, reporting 33,745 EP procedures, of which 4,561 (13.52%) were 
A-AF (min = 3; max = 1091; average = 88; SD = 159, median = 49; IQR = 22–81). 
Production cost for A-AF amounted to c9455 (m-mat) and c8868 (m-geo): consum-
ables (ablation and diagnostic catheters, transeptal needles, transeptal sheaths, and 
other devices) accounted for 61% of total cost; hospital stay 15%; intra-procedural 
costs (room occupancy, staff, anaesthesia and equipment) 20%; pre-procedural tests 
4%. Difference of DRG-518 tariff vs. hospital incurred costs: m-mat c−4079 (−43%) 
or m-geo c−3492 (−35%). Cost of production appears more under-remunerated in 
Lazio (−54%), Lombardia (−46%), Veneto, Umbria (−45%). The imbalance was 
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−42%/−44% when centres were grouped by the number of A-AF procedures per-
formed. Total cost of A-AF (including 2 years post-procedure follow-up) was c10,163 
(m-mat) or c9,632 (m-geo). Cost of follow-up represented only 8% on total cost of 
A-AF. CONCLUSIONS: The cost of AF ablation procedures is signiﬁ cant and is 
largely under-funded by the DRG tariff, which showed inadequate to remunerate 
hospitals in all Italian Regions.
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COST CONSEQUENCES AND RESOURCE UTILIZATION IN 
TRANSCATETHER AORTIC VALVE IMPLANTATION (TAVI) AS A 
SUBSTITUTION FOR HIGH RISK SURGICAL PATIENTS
Webb PP1, Carroll GD1, Smith D2
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Swansea, UK
OBJECTIVES: TAVI is a novel interventional procedure and is considered as an 
alternative to surgery in high risk patients with severe aortic stenosis. For commis-
sioning purposes, a cost consequences model was derived to look at the impact of 
substituting TAVI for high risk conventional surgery patients. METHODS: The cost 
consequence included hospital LOS on CITU, HDU and ward and pacemakers implan-
tation costs. Twenty-ﬁ ve patients were retrospectively identiﬁ ed by clinicans with 
TAVI experience who might have been eligible to receive TAVI in the previous year 
of introduction of TAVI on the market. The patient speciﬁ cation was aligned with the 
TAVI device CE marking criteria. The average TAVI patient cost was obtained from 
a manufacturer sponsored economic model which used UK patient level data from 
their sponsored registry. The hospital’s local database was used for unit costs. Costs 
were calculated based on mean values for CITU (critical intensive care unit), HDU 
(high dependency unit), ward and pacemaker implantation. We also calculated the 
mean cost per case based on the total length of stay (LOS) for CITU, HDU ward and 
pacemaker implants of each of the isolated AVR and AVR plus valvular disease (AVR 
+ CABG) population. RESULTS: The total cost based on mean LOS values was 
£21,460 for isolated AVR and £23,032 for AVR + CABG. The cost per TAVI case 
based on total LOS was £24,721 compared to £49,982 for AVR + CABG. CONCLU-
SIONS: The cost consequence model was sensitive to long LOS on CITU and HDU 
in the AVR plus CABG group. Using a cost consequences model TAVI was at worst 
cost neutral and at best most likely to deliver substantial savings in this centre in this 
well deﬁ ned patient population. This ﬁ nding is signiﬁ cant in assessment of the “real” 
cost impact for substituting TAVI for high risk conventional surgery.
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HEALTH ECONOMIC ASSESSMENT OF FERRIC CARBOXYMALTOSE IN 
PATIENTS WITH IRON DEFICIENCY AND CHRONIC HEART FAILURE IN 
THE FAIR-HF TRIAL
Gutzwiller FS, Blank PR, Schwenkglenks M, Szucs TD
Institute of Pharmaceutical Medicine/ECPM, University of Basel, Basel, Switzerland
OBJECTIVES: Chronic heart failure (CHF) is associated with poor quality of life 
resulting from physical and psycho-social limitations. The FAIR-HF trial showed 
clinical and quality of life beneﬁ ts of iron deﬁ ciency treatment in CHF patients using 
ferric carboxymaltose (FCM), an intravenous (i.v.) iron preparation. This study evalu-
ated the cost-effectiveness of iron repletion using FCM in CHF patients, from the 
perspectives of the statutory health insurance (Germany) and the National Health 
Service (UK). METHODS: Using data from FAIR-HF, a randomized, double-blind, 
controlled clinical trial (n = 459), per-patient costs and clinical effectiveness of FCM 
were estimated. Economic assessment was based on published costs associated with 
New York Heart Association (NYHA) functional classes. Effectiveness was assessed 
as the number of QALYs gained, derived from EQ-5D scores. The ICER of FCM was 
determined compared to placebo. Time horizon of this within-trial analysis was 24 
weeks. RESULTS: In the FAIR-HF trial, NYHA classes were signiﬁ cantly improved 
in the FCM group compared with placebo (P < 0.001). Estimated per-patient costs 
(excluding iron costs) were c2625 and c2919 (Germany), and £4155 and £4621 (UK), 
for FCM and placebo arms, respectively. Based on the reimbursed price for FCM in 
Germany and UK (c28 and £19 per 100 mg iron) and the mean iron dosage of the 
clinical study (1850 mg) plus administration costs, a net investment of c530 and £68 
per patient would be required. FCM resulted in an estimated gain of 0.0254 QALYs 
over the study period. The ICER of FCM ranged from c20,872 to £2,682 per QALY 
gained for the FAIR-HF dosing regimen, compared to placebo. ICER-differences result 
from disparities in administration and medication costs. CONCLUSIONS: From the 
German and UK payers’ perspective, managing iron deﬁ ciency in CHF patients using 
i.v. FCM can be considered cost-effective. Improved symptoms and better quality of 
life contribute to economic beneﬁ ts seen with FCM.
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ECONOMIC PERFORMANCE OF DABIGATRAN ETEXILATE FOR 
PRIMARY VTE PREVENTION FOLLOWING TOTAL HIP AND KNEE 
REPLACEMENT SURGERY IN ITALY
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OBJECTIVES: To estimate cost/effectiveness and cost/utility of dabigatran etexilate 
(DBG) compared to standard care for the prevention of venous thromboembolism 
(VTE) secondary to total hip replacement (THR) or total knee replacement (TKR) in 
Italy. METHODS: A decision analytic, Markov-chain based model originally devel-
oped for the UK has been adapted to the Italian context. Clinical outcomes, including 
incidences of VTE and treatment-related adverse events, were extrapolated from head-
to-head, phase III trials of DBG vs. enoxaparin. For the other low molecular weight 
heparins (LMWHs), indirect comparisons were performed on the basis of equal 
effectiveness assumptions. The adaptation involved cost and demographic character-
istics, leaving clinical and utility data unvaried. Costs are taken from national obser-
vational studies, where available. Otherwise, current prices and tariffs are applied. 
Resources consumption where derived from practice guidelines or taken from those 
estimated for the UK model. According to the prevalent national practice, extended 
prophylaxis has been considered for both surgical procedures. Time horizon of the 
analysis is patients’ lifetime. RESULTS: Compared to LMWHs, DBG is associated to 
an expected increase of 0.019 LYs and 0.014 QALYs per THR patient and of 0.024 
LYs and 0.019 QALYs per TKR patient. DBG-related cost is lower than competitors 
in both procedures, with a mean difference ranging between c82 and c109 for THR, 
and 100 and 135 for TKR, depending on the considered comparator. Higher acquisi-
tion costs for DBG are completely offset and inverted by avoided administration 
expenses and, less importantly, by savings on VTE management. Probabilistic sensitiv-
ity analysis estimates that, for a willingness to pay threshold of £30,000 (~c33,500)/
QALY, DBG is associated to a probability of being cost/effective of about 98% for 
THR and of 90% for TKR. CONCLUSIONS: On average DBG dominates LMWHs, 
as it’s expected to be cost-saving and non-inferior in terms of efﬁ cacy and safety.
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COST-EFFECTIVENESS OF FONDAPARINUX VS. ENOXAPARIN IN 
NON-ST-ELEVATION ACUTE CORONARY SYNDROMES IN RUSSIA
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OBJECTIVES: To assess cost-effectiveness of fondaparinux versus enoxaparin in 
patients with non-ST-elevation acute coronary syndrome in Russia. METHODS: A 
decision tree model was created incorporating the outcomes associated with 2 anti-
thrombotic approaches from OASIS-5 trial: enoxaparin (1 mg/kg every 12 hours) 
versus fondaparinux (2.5 mg/day). Probabilities of complications (e.g., myocardial 
infarction, stroke, major bleeding at 9, 30 and 180 days) were calculated. Data on 
resource utilization (staff, drugs, materials, laboratory, and equipment), diagnosis and 
treatment came from the hospital survey. Resources were valued in internal hospital 
prices based on obligatory medical insurance tariffs (as of 2008). The incremental 
cost-effectiveness ratio for fondaparinux per death avoided and per major bleeding 
episode avoided versus enoxaparin was quantiﬁed. Sensitivity analysis was performed. 
RESULTS: The cost analysis showed that fondaparinux would generate a cost saving 
of 1634 RUR (c43), 1902 RUR (c50) and 2167 RUR (c57) per patient at 9, 30 and 
180 days respectively. When cost and clinical results were extrapolated to cost-
effectiveness, fondaparinux was dominant (less costly and more effective in terms of 
death avoided and major bleeding episode avoided). The sensitivity analysis proved 
that costs of pharmacotherapy with fondaparinux and enoxaparin had the biggest 
impact on results. CONCLUSIONS: Fondaparinux is a more cost-effective option 
than enoxaparin in treatment of patients with non-ST-elevation acute coronary syn-
drome from the hospital perspective in Russia.
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POTENTIAL COST-EFFECTIVENESS OF A BIOMARKER TEST TO 
RECLASSIFY PATIENTS WITH AN INTERMEDIATE RISK BASED ON THE 
FRAMINGHAM RISK SCORE INTO A LOWER OR HIGHER CATEGORY 
TO OPTIMIZE STATIN THERAPY
Burgers LT, Redekop WK, Severens JL
Erasmus University Rotterdam, Rotterdam, The Netherlands
OBJECTIVES: The Framingham Risk Score is a well-accepted tool to estimate the 
10-year risk of developing coronary heart disease (CHD). However, many patients 
fall into the intermediate risk category. Improved discrimination within this category 
is necessary to prevent CHD and side-effects of statins therapy efﬁ ciently. This eco-
nomic evaluation calculated the potential lifetime cost-effectiveness of a novel bio-
marker test which helps to decide whether patients with an intermediate risk should 
be treated with statins. METHODS: Prognosis of patients with an intermediate risk 
was simulated with a Markov chain Monte Carlo model to estimate the potential 
lifetime costs and effects (life-years (LY)) for three strategies: treat all with statins, 
treat none with statins or use a test to select patients for statin treatment. Costs were 
calculated for the The Netherlands using a health care sector perspective. Values for 
all input parameter were derived from the literature. RESULTS: A strategy using a 
perfect test for a 55-year old man would be slightly more expensive than the treat-none 
option (c1966 vs. c1941) but less expensive than the treat-all option (c5374). The test 
and the treat-all option would be equally effective (24.45 LY) and more effective than 
the treat-none option (24.3 LY). An ICER of c170 versus treat-none indicates that it 
is a biomarker test with great potential. Results were sensitive to uncertainties regard-
ing model parameters such as the sensitivity, speciﬁ city and costs of the test, as well 
as CHD risk, and the costs and effectiveness of statins. CONCLUSIONS: A test to 
reclassify patients in the Framingham intermediate risk group into higher and lower 
risk categories has the potential to optimize cost-effectiveness by preventing CHD and 
reduce the risk of drug side-effects. Values used in this model (e.g., test sensitivity and 
speciﬁ city) can be adjusted wherever needed to determine whether continued develop-
ment of a biomarker is worthwhile.
